
Amgen will pay an initial $55m and up to $666m in cash subject to milestones.
US-based developer of social advertising displays for businesses exits for undisclosed amount.
US-listed pharmaceuticals company Merck to spin off Organon after acquisition
Post-acquisition, the DMGT-backed online vehicle marketplace's valuation will be nearly three times that of its last funding round five months ago.
The Tencent-backed vertical take-off and landing jet developer is joining forces with the Nasdaq-listed Qell Acquisition Corp.
The Agilent Technologies-backed tissue analysis device maker has selected the Nasdaq Global Select Market for its initial public offering.
Novo, Sanofi and Merck & Co all scored exits as the cancer drug developer, which had been spun off by Biox Biosciences, floated in a $101m offering.